Sequelae of inflammatory diseases of central nervous system
Chapter 6:Diseases of the nervous system
ICD-10 G09 is a billable code used to indicate a diagnosis of sequelae of inflammatory diseases of central nervous system.
G09 is used to classify sequelae resulting from inflammatory diseases of the central nervous system (CNS), including infections such as meningitis, encephalitis, and brain abscesses. These conditions can lead to long-term neurological deficits, cognitive impairments, and other complications that persist after the initial infection has resolved. The sequelae may manifest as motor deficits, sensory disturbances, seizures, or cognitive dysfunction, significantly impacting the patient's quality of life. Accurate coding of G09 requires a thorough understanding of the patient's history of CNS infections and the specific sequelae they are experiencing. Documentation should detail the nature of the initial inflammatory disease, the treatment received, and the ongoing effects on the patient's health. This code is crucial for tracking the long-term impacts of CNS infections and ensuring appropriate care and resource allocation.
Detailed history of CNS infections, neurological assessments, and treatment plans.
Patients with a history of meningitis presenting with cognitive deficits or seizures.
Ensure that all neurological assessments are documented to support the diagnosis of sequelae.
Comprehensive records of the infectious disease treatment and follow-up care.
Patients recovering from encephalitis with ongoing neurological symptoms.
Document the timeline of infection and recovery to clarify the relationship to sequelae.
Used for follow-up visits for patients with sequelae of CNS infections.
Document the patient's history, current symptoms, and any neurological assessments.
Neurologists should ensure detailed neurological evaluations are included.
G09 should be used when a patient has a documented history of an inflammatory disease of the CNS and is experiencing ongoing sequelae related to that condition.